Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
malaria 2 infectiousdiseases
mucocutaneous leishmaniasis 1 infectiousdiseases
visceral leishmaniasis 2 infectiousdiseases
cutaneous leishmaniasis 2 infectiousdiseases
infectious disease 2 infectiousdiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
cutaneous leishmaniasis 2395 Leishmania species identified worldwide [[5]]. Unlike other common forms of leishmaniasis, such as cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (ML), and post-kala-azar dermal leishmaniasis (PKDL), VL symptoms
cutaneous leishmaniasis 2429 worldwide [[5]]. Unlike other common forms of leishmaniasis, such as cutaneous leishmaniasis (CL), muco cutaneous leishmaniasis (ML), and post-kala-azar dermal leishmaniasis (PKDL), VL symptoms usually occur internally [[1]], meaning
infectious disease 16403 epidemic and narrow the range of the insecticide spraying.As the most effective control strategy for infectious disease s, the successful vaccination on VL is long-awaited for the VL afflicted countries. The experiment on
infectious disease 35465 consider the four following aspects:building more sophisticated mathematical models to explain underlying infectious disease transmission dynamics,including real-world data to aid model validation and verifications,exploring
malaria 1581 IntroductionVisceral leishmaniasis (VL), or kala-azar, is a protozoan disease that, second only to malaria in numbers of fatalities, afflicts millions of people worldwide [[1]]. VL is primarily distributed in
malaria 14240 sub-Saharan Africa, Latin American, Thailand, Pakistan, and Iran show that ITNs could reduce infections with malaria by 17%–62%. In 2015, Picado et al. summarized the results of the KALANET project to analyze ITN effectiveness.
mucocutaneous leishmaniasis 2425 worldwide [[5]]. Unlike other common forms of leishmaniasis, such as cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (ML), and post-kala-azar dermal leishmaniasis (PKDL), VL symptoms usually occur internally [[1]], meaning
visceral leishmaniasis 2712 leishmaniasis. Based on different kinds of susceptible species, VL can be classified as anthroponotic visceral leishmaniasis (AVL) or zoonotic visceral leishmaniasis (ZVL). AVL, which is transmitted between humans via vector
visceral leishmaniasis 2753 susceptible species, VL can be classified as anthroponotic visceral leishmaniasis (AVL) or zoonotic visceral leishmaniasis (ZVL). AVL, which is transmitted between humans via vector carriers, is primarily caused by L. donovani

You must be authorized to submit a review.